Discuss current M&A market trends for U.S. biotech companies, focusing on traditional and non-traditional exit routes and explore trends and creative deal structures, such as reverse mergers of private companies with strong assets into "wounded" public companies with cash, but no clinical assets. As part of the session, the panel will also discuss provisions in license/collaboration agreements that are most critical to biotech companies preserving an ultimate M&A exit, including standstills, change of control provisions, retention of commercial rights and other provisions that create or preserve value for a future M&A transaction.

• Share updates on recent noteworthy trends in the biotech M&A market and implications for U.S. biotech companies considering an M&A transaction
• Hear "war stories" and "lessons-learned" from industry leaders who have been involved in recent biotech M&A transactions
• Offer suggestions to help ensure a successful M&A transaction for U.S. biotech companies